Program Overview
This seminar will examine the cardiovascular impact of cancer therapies, with a focus on the recognition and management of treatment-related cardiotoxicity. Presentations will include a case-based discussion of immune checkpoint inhibitor–associated myocarditis, an overview of anthracycline and HER2-related cardiotoxicity, and practical treatment strategies.
Target Audience
This activity is intended for trainees, fellows, physicians, APPs, nurses, pharmacists and pharmacologists who care for patients with heart failure.
Learning Objectives
Following this activity, participants will be better able to:
1. Recognize the clinical presentation, diagnostic evaluation, and management strategies for ICE-associates myocarditis.
2. Evaluate strategies for mitigating risk in patients with cancer therapy-related cardiac dysfunction.
3. Identify the cardiovascular risks of anthracyclines and HER2-targeted therapies and apply strategies for prevention, cardio protection, and permissive cardiotoxicity.
Agenda
Welcome and Introductions
Ashley Hardin
Immune Checkpoint Inhibitor - Associated Myocarditis: A Case-Based Discussion of Diagnosis and Management
Jean Kim
Evaluate Strategies for Mitigating Risk in Patients with Cancer Therapy-Related Cardiac Dysfunction
Diego Sadler
What Is an Ounce of Prevention Worth? Prevention and Management Strategies for Cancer Therapy-Related
Aaron Bagnola
Panel Discussion: All Faculty Members
Ashley Hardin, Jean Kim, Diego Sadler, Aaron Bagnola, Deepa Gopal
Faculty
Elizabeth Ashley Hardin, MD, FHFSA, UT Southwestern Medical CenterDeepa Gopal, MD, MSc, MD, Boston University Medical CenterAaron Bagnola, PharmD, The Ohio State University Medical CenterJean Kim, MD, UT Southwestern Medical CenterDiego Sadler, MD, Cleveland Clinic
Faculty Disclosures
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
Aaron Bagnola, PharmD
Elizabeth Ashley Hardin, MD, FHFSA
Jean Kim, MD
Diego Sadler, MD
Shauna Wheeler, MSL (CE Review)
The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
Accreditation Statement - THIS IS THE UPDATED VERSION FROM SHAUNA
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.00 contact hours.
The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.00 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): UAN JA4008267-0000-26-001-L01-P (live); UAN JA4008267-0000-26-002-H01-P (home study)
The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This activity is approved for 1.00 contact hours (0.10 CEUs) of general continuing education for health care professionals.
Successful completion of this activity includes the completion of the post-course evaluation.
Important Dates
Originally recorded April 30, 2026